A 70-year-old cisgender man with HIV and hypertension presented to a clinic to discuss a potential update to his antiretroviral therapy. He has been taking tenofovir DF-emtricitabine plus raltegravir for 7 years with a routinely undetectable HIV RNA level but reports intermittently forgetting the second daily dose of raltegravir. In the past year, his serum creatinine has been slowly rising, with an estimated glomerular filtration rate now of 50 mL/min and 1+ proteinuria. A prior HLA-B*5701 test was positive. You are considering switching to the single-tablet regimen bictegravir-tenofovir alafenamide-emtricitabine.